TRBV6-2: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Target Name: TRBV6-2

NCBI ID: G28605

TRBV6-2

Other Name(s): TRBV62 | TCRBV6S2 | TCRBV13S2A1T | T cell receptor beta variable 6-2 | TCRBV13S2

TRBV6-2: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are a group of disorders that affect the nervous system and can result in a wide range of debilitating and fatal conditions. These diseases include Alzheimer's disease, Parkinson's disease, and Huntington's disease, among others. They are characterized by the progressive loss of brain cells and the formation of aggregates of toxic substances, which can cause a range of symptoms and impairments.

TRBV6-2 is a protein that is expressed in the brain and has been shown to be involved in the development and progression of neurodegenerative diseases. It is a member of the TRBV6 family, which includes several other proteins that have also been implicated in neurodegenerative diseases.

The TRBV6-2 protein is expressed in the brain and has been shown to be involved in the development and progression of neurodegenerative diseases. (Image: courtesy of PubMed)

One of the main functions of TRBV6-2 is its role in the formation of neurofibrillary tangles, which are composed of abnormal aggregates of the protein tau. Neurofibrillary tangles are thought to play a key role in the development of neurodegenerative diseases, as they can cause the build-up of toxic substances and disrupt the normal functioning of neurons.

In addition to its role in the formation of neurofibrillary tangles, TRBV6-2 has also been shown to be involved in the regulation of the survival and proliferation of neural stem cells. These cells are responsible for the development and maintenance of the nervous system, and their dysfunction has been implicated in a wide range of neurodegenerative diseases.

TRBV6-2 has also been shown to play a role in the development of neurodegenerative diseases in animal models. For example, studies have shown that TRBV6-2-deficient mice have increased levels of neurofibrillary tangles and were more susceptible to neurodegenerate behaviors, such as the development of Alzheimer's disease-like symptoms.

Despite these promising findings, more research is needed to fully understand the role of TRBV6-2 in the development and progression of neurodegenerative diseases. One potential way to study its role is to use it as a drug target. By targeting TRBV6-2 with small molecules or other compounds, researchers may be able to prevent or reverse the development of neurodegenerative diseases.

Another potential way to study TRBV6-2 is as a biomarker. By measuring the levels of TRBV6-2 in brain tissue or fluids, researchers may be able to monitor the progression of neurodegenerative diseases and the effectiveness of potential treatments.

Overall, TRBV6-2 is a protein that has the potential to be a drug target and biomarker for the treatment of neurodegenerative diseases. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: T Cell Receptor Beta Variable 6-2

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV6-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV6-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets